Financial reports
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-K/A
2019 FY
Annual report (amended)
15 Sep 20
10-Q
2020 Q2
Quarterly report
17 Aug 20
NT 10-Q
Notice of late quarterly filing
10 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
10-K
2019 FY
Annual report
6 Mar 20
10-Q
2019 Q3
Quarterly report
1 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
1 Mar 19
Current reports
8-K
Entry into a Material Definitive Agreement
17 Nov 20
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
17 Nov 20
8-K
Regulation FD Disclosure
5 Oct 20
8-K
Entry into a Material Definitive Agreement
1 Oct 20
8-K
Other Events
17 Aug 20
8-K
Amag Pharmaceuticals Announces Second Quarter 2020 Financial Results
6 Aug 20
8-K
Amag Pharmaceuticals Completes Divestment of Women’s Health Assets
27 Jul 20
8-K
Amag Pharmaceuticals and Norgine B.V. Enter into Exclusive Licensing Agreement to Commercialize Ciraparantag In Europe, Australia and New Zealand
23 Jul 20
8-K
Amag Pharmaceuticals Announces Leadership Changes
11 Jun 20
8-K
Submission of Matters to a Vote of Security Holders
4 Jun 20
Registration and prospectus
15-12B
Securities registration termination
27 Nov 20
POSASR
Automatic shelf registration (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
Proxies
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
15 Apr 20
DEFA14A
Additional proxy soliciting materials
8 Oct 19
DEFA14A
Additional proxy soliciting materials
4 Oct 19
DFRN14A
Revised proxy by non-management
26 Sep 19
DFAN14A
Additional proxy materials by non-management
26 Sep 19
DEFA14A
Additional proxy soliciting materials
23 Sep 19
DEFC14A
Proxy in contested solicitation
20 Sep 19
DFAN14A
Additional proxy materials by non-management
16 Sep 19
DFAN14A
Additional proxy materials by non-management
16 Sep 19
Other
CT ORDER
Confidential treatment order
6 May 20
CT ORDER
Confidential treatment order
6 May 20
CT ORDER
Confidential treatment order
6 May 20
CT ORDER
Confidential treatment order
6 May 20
CORRESP
Correspondence with SEC
16 Sep 19
UPLOAD
Letter from SEC
16 Sep 19
CT ORDER
Confidential treatment order
5 Mar 19
CT ORDER
Confidential treatment order
15 Feb 19
CT ORDER
Confidential treatment order
11 Sep 18
CT ORDER
Confidential treatment order
5 Jun 18
Ownership
SC 13G/A
Camber Capital Management LP
16 Feb 21
SC 13G/A
Palo Alto Investors LP
16 Feb 21
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
10 Feb 21
4
DAVEY SCOON
17 Nov 20
4
Anne M. Phillips
17 Nov 20
4
DAVID EDWARD JOHNSON
17 Nov 20
4
Change in insider ownership
17 Nov 20
4
Kelly Schick
17 Nov 20
4
JAMES R SULAT
17 Nov 20
4
Joseph Vittiglio
17 Nov 20